Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2

被引：0
|
作者：
Shvartsbart, Artem
Ito, Koichi
Rager, Joseph
Hulse, Michael
Agarwal, Anjana
Vykuntam, Komali
Burtell, Jessica
Wang, Min
Kurian, Justin
Cowart, Miles
Cote, Joy
Stahl, Nick
Sivakumar, Monisha
Reichelderfer, Anthony
Carter, Jack
Grego, Alexander
Moore, Andrew
Bhagwat, Neha
Kuskovsky, Ross
Ganesan, Shanthi
Ruepp, Stefan
Emm, Tom
Pitis, Philip
Basch, Corey
Bersch, Klare
Pan, Yongchun
Mei, Song
Leal, Raul
Rose, John
Roth, Dani
Xu, Chaoyi
Cao, Ganfeng
Vaddi, Kris
Lee, Sang Hyun
Geeganage, Sandy
Combs, Andrew
Scherle, Peggy
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4503
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical characterization of PRT3789, a potent and selective SMARCA2 targeted degrader
    Hulse, Michael
    Agarwal, Anjana
    Wang, Min
    Carter, Jack
    Sivakumar, Monisha
    Vidal, Brian
    Brown, Justin
    Moore, Andrew
    Grego, Alexander
    Bhagwat, Neha
    Rager, Joseph
    Lu, Liang
    Basch, Corey
    Bersch, Klare
    Dai, Chaofeng
    Pitis, Philip
    Combs, Andrew
    Ruggeri, Bruce
    Vaddi, Kris
    Scherle, Peggy
    Ito, Koichi
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Discovery of potent, highly selective and orally efficacious SMARCA2 degraders
    Leng, Lingying
    Yang, Lin
    Tu, Wenbin
    Rej, Rohan
    Allu, Srinivasa Rao
    Huang, Liyue
    Jiang, Wei
    Wang, Yu
    Stuckey, Jeanne
    Sarkari, Farzad R.
    Wang, Meilin
    Wang, Lu
    Wen, Bo
    Sun, Duxin
    Wang, Shaomeng
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Selective and orally bioavailable SMARCA2 targeted degraders induce synthetic lethality in SMARCA4-deficient solid tumor
    Ito, Koichi
    Shvartsbart, Artem
    Rager, Joseph
    Agarwal, Anjana
    Hulse, Michael
    Vykuntam, Komali
    Wang, Min
    Kurian, Justin
    Cowart, Miles
    Cote, Joy
    Sivakumar, Monisha
    Carter, Jack
    Burtell, Jessica
    Grego, Alex
    Moore, Andrew
    Bhagwat, Neha
    Ruepp, Stefan
    Emme, Tom
    Lu, Liang
    Pitis, Philip
    Basch, Corey
    Bersch, Klare
    Mei, Song
    Leal, Raul
    Rose, John
    Roth, Danielle
    Cao, Ganfeng
    Vaddi, Kris
    Geeganage, Sandy
    Ruggeri, Bruce
    Combs, Andrew
    Scherle, Peggy
    CANCER RESEARCH, 2023, 83 (07)
  • [4] Development of pharmacodynamic assays for quantifying SMARCA2 protein degradation and target gene expression in response to a SMARCA2 degrader (PRT3789)
    Moore, Andrew
    Bachner, Carly
    Srinivasan, Lalitha
    Kurup, Pradeep
    Grego, Alex
    Vitkovitsky, Caroline
    Ito, Koichi
    Bhagwat, Neha
    Scherle, Peggy
    CANCER RESEARCH, 2023, 83 (07)
  • [5] A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation
    Dagogo-Jack, I.
    Dowlati, A.
    Guo, R.
    Awad, M. M.
    Swalduz, A.
    Calvo, E.
    Garcia, V. Moreno
    Adjei, A. A.
    Lorusso, P.
    Punekar, S.
    Leal, T. A.
    Yap, T. A.
    Italiano, A.
    Novotny, W.
    Tankersley, C.
    Rowe, S.
    Paris, G.
    Sun, W.
    Spira, A. I.
    Besse, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S493 - S494
  • [6] Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders
    Li, Zhenwu
    Harikrishnan, Lalgudi S.
    Xu, Guozhang
    Samanta, Debangshu
    Clemente, Jose C.
    Leng, Lingying
    Tu, Wenbin
    Yang, Lin
    Huang, Liyue
    Wang, Mi
    Wang, Shaomeng
    Deng, Qiaolin
    Behshad, Elham
    Nagilla, Rakesh
    Orth, Peter
    Rice, Cory
    Strickland, Corey
    Mohammad, Helai P.
    Priestley, E. Scott
    Sui, Zhihua
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 68 (02) : 1134 - 1154
  • [7] Development of potent, highly selective and efficacious SMARCA2 degraders
    Yang, Lin
    Tu, Wenbin
    Huang, Liyue
    Leng, Lingying
    Jiang, Wei
    Wang, Meilin
    Wen, Bo
    Sun, Duxin
    Stuckey, Jeanne
    Wang, Shaomeng
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD).
    Bhagwat, Shripad V.
    Zhao, Baohui
    Shen, Weihua
    Mur, Cecilia
    Barr, Robert
    Kindler, Lisa J.
    Rubio, Almudena
    Bastian, Jolie A.
    Cohen, Jeffrey D.
    Mattioni, Brian E.
    Yuen, Eunice
    Baker, Thomas K.
    Castanares, Mark A.
    Fei, Dongling
    Manro, Jason R.
    Lallena, Maria Jose
    Peng, Sheng-Bin
    de Dios, Alfonso
    CANCER RESEARCH, 2021, 81 (13)
  • [9] Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers
    Ito, Koichi
    Hulse, Michael
    Agarwal, Anjana
    Carter, Jack
    Sivakumar, Monisha
    Vykuntam, Komali
    Wang, Min
    Cowart, Miles
    Cote, Joy
    -MacDonald, William Gowen
    Torres, Brian Vidal
    Kurian, Justin
    Bhagwat, Neha
    Fultang, Norman
    Grego, Alexander
    Moore, Andrew
    Schwab, Ashley
    Burtell, Jessica
    Osinubi, Olusola Peace
    Spruance, Jacob
    Lu, Liang
    Pitis, Philip
    Basch, Corey
    Bersch, Klare
    Dai, Chaofeng
    Leal, Raul
    Shvartsbart, Artem
    Cao, Ganfeng
    Shen, Bo
    Wen, Patrick
    Rager, Joseph
    Kuskovsky, Ross
    Landman, Bob
    Emm, Tom
    Ruepp, Stefan
    Qin, Chunhua
    Paris, Gina
    Xavier, Jennifer
    Chiaverelli, Rachel
    Lee, Sang Hyun
    Geeganage, Sandy
    Lin, Hong
    Heiser, Diane
    Ruggeri, Bruce
    Babbar, Naveen
    Combs, Andrew
    Scherle, Peggy
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [10] A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
    Kofink, Christiane
    Trainor, Nicole
    Mair, Barbara
    Woehrle, Simon
    Wurm, Melanie
    Mischerikow, Nikolai
    Roy, Michael J.
    Bader, Gerd
    Greb, Peter
    Garavel, Geraldine
    Diers, Emelyne
    McLennan, Ross
    Whitworth, Claire
    Vetma, Vesna
    Rumpel, Klaus
    Scharnweber, Maximilian
    Fuchs, Julian E.
    Gerstberger, Thomas
    Cui, Yunhai
    Gremel, Gabriela
    Chetta, Paolo
    Hopf, Stefan
    Budano, Nicole
    Rinnenthal, Joerg
    Gmaschitz, Gerhard
    Mayer, Moriz
    Koegl, Manfred
    Ciulli, Alessio
    Weinstabl, Harald
    Farnaby, William
    NATURE COMMUNICATIONS, 2022, 13 (01)
12345